CellMax Life Inc (合度精密生物科技) yesterday launched a blood-testing service in Taiwan that focuses on screening for early-stage cancer.
The company’s flagship product, CellMax CRC-Protect, is a multi-biomarker blood test aimed at the early detection of colorectal cancer.
The product has been used by more than 500 patients at a number of local hospitals, including Linkou Chang Gung Memorial Hospital (林口長庚紀念醫院).
“We aim to transform cancer care away from expensive, intractable late stages to early, more treatable stages,” CellMax Life co-founder and chief operating officer Atul Sharan told a news conference in Taipei yesterday.
Much of the biotechnology sector focuses on expensive late-stage drugs that might not be accessible in developing countries, while survival rates for patients with late-stage cancer diminish rapidly, Sharan added.
The company’s proprietary CMx technology platform screens for cancer by detecting traces of circulating early-stage tumor cells that are shed from the primary tumor site into the bloodstream, CellMax science team chief Shao Hung-jen (邵宏仁) said.
Abnormal cells should be detected by the screening product before they turn into precancerous cells and metastasize, Shao said.
The platform uses a biomimetic, lipid-bilayer coated microfluidic chip to identify circulating tumor cells cells in patients’ blood samples, Shao said.
As the test requires a blood sample, it is an attractive option for patients who are averse to fecal occult blood tests, stool samples or colonoscopies, Shao said.
However, the test is not intended to replace existing examinations, but is designed to be used as an additional diagnostic tool by physicians, Shao said.
A woman said in a testimonial video that after using a CellMax screening product and consulting her physician, she agreed to have intestinal surgery that removed eight polyps and minimized her chances of contracting colon cancer.
Chao recommended that people who are at high risk of developing colon cancer undergo annual screening, adding that each of the firm’s tests costs about NT$15,000.
CellMax’s other products include testing of genetic risk, liquid biopsies and recurrence monitoring.
The company also announced US$9 million in series A-1 venture funding to scale commercial operations of its blood test product portfolio.
The funding was led by Silicon Valley-based Artiman Ventures and several Taiwanese venture investors, including Acer founder and former chairman Stan Shih (施振榮).
The company has so far accumulated US$14 million in venture capital.
NO VIRUS BLUES: A SEMI Taiwan official said that the virus does not slow down the global semiconductor industry’s investment in manufacturing equipment The production value of the nation’s semiconductor industry is expected to grow 16.7 percent this year from last year, outpacing the global industry’s 3.3 percent growth, industry association SEMI said yesterday. That would help Taiwan safeguard its second spot in the global semiconductor market with a production value of more than NT$3 trillion (US$102.73 billion), SEMI Taiwan president Terry Tsao (曹世綸) told a media briefing in Taipei for the Semicon Taiwan trade show beginning today. The global semiconductor industry’s production value is expected to increase to US$426 billion this year, SEMI said. In terms of semiconductor equipment investment, equipment billings from Taiwanese firms
Intel Corp has received licenses from US authorities to continue supplying certain products to Huawei Technologies Co (華為), a company spokesman said yesterday. Washington has been pushing governments around to world to squeeze out Huawei, saying that the telecom giant would hand data to Beijing for espionage. From Monday last week, new curbs have barred US companies from supplying or servicing Huawei. This week, the state-backed China Securities Journal reported that Intel had received permission to supply Huawei. China’s Semiconductor Manufacturing International Corp (SMIC, 中芯國際), which uses US-origin equipment to make chips for Huawei and other companies, last week confirmed that it had sought
Taipei Times: When do you think the hospitality industry can return to how it was before the COVID-19 pandemic? How does Formosa International Hotels Group (FIH, 晶華酒店集團) fare this quarter and beyond? FIH chairman Steve Pan (潘思亮): The virus outbreak will have a serious impact on business travel, driven mainly by meetings, incentive travel, conferences and exhibitions over the past three decades. For the past six months, many businesspeople have grown used to exchanging information on the Internet, where more people can participate. The trend might sustain for three to five years until people are vaccinated and it is safe to
DIGITAL COMMERCE: In 2016, only 2 percent of orders were delivered in Taiwan, but that has risen to 10 percent, Foodpanda Taiwan Co operations director Nick Yu said Online food delivery platforms have seen explosive growth in Taiwan this year, helped by business opportunities related to the COVID-19 pandemic, company executives said at a digital commerce conference in Taipei yesterday. When the threat of COVID-19 kept people from going out to eat, more people experimented with ordering food deliveries online, Foodpanda Taiwan Co Ltd (富胖達) operations director Nick Yu (余岳勳) said. Foodpanda started operations in Taiwan in 2012. “We experienced 5,000 percent growth in the past 24 months,” Yu said. “That’s more than the previous six years combined.” In 2016, only 2 percent of food orders were delivered in Taiwan, but that